High-efficacy disease-modifying therapies despite clinical stability: the role of patients on treatment decisions (PERCEPTIONS-MS Study)

被引：0
|
作者：
Saposnik, G. [1 ,2 ,3 ]
Sempere, A. P. [4 ]
Aladro-Benito, Y. [5 ]
Sotoca, J. [6 ]
Bakdache, F. [7 ]
Terzaghi, M. [2 ,8 ]
Maurino, J. [9 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Dept Med, Div Neurol, Toronto, ON, Canada
[2] St Michaels Hosp, Decis Neurosci Unit, Toronto, ON, Canada
[3] Univ Zurich, Lab Social & Neural Syst Res, Dept Econ, Zurich, Switzerland
[4] Hosp Gen Univ Alicante, Dept Neurol, Alicante, Spain
[5] Hosp Univ Getafe, Dept Neurol, Getafe, Spain
[6] Hosp Univ Mutua Terrassa, Dept Neurol, Terrassa, Spain
[7] Hoffmann La Roche Ltd, Neurosci, Med Affairs, Mississauga, ON, Canada
[8] Univ Toronto, Li Ka Shing Knowledge Inst, Toronto, ON, Canada
[9] Roche Farma SA, Med Dept, Madrid, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1433
引用
收藏
页码：800 / 800
页数：1
相关论文
共 50 条
  • [21] Beyond lines of treatment: embracing early high-efficacy disease-modifying treatments for multiple sclerosis management
    Oreja-Guevara, Celia
    Martinez-Yelamos, Sergio
    Eichau, Sara
    Llaneza, Miguel Angel
    Martin-Martinez, Jesus
    Pena-Martinez, Joaquin
    Meca-Lallana, Virginia
    Alonso-Torres, Ana Maria
    Moral-Torres, Ester
    Rio, Jordi
    Calles, Carmen
    Ares-Luque, Adrian
    Ramio-Torrenta, Lluis
    Marzo-Sola, Maria Eugenia
    Prieto, Jose Maria
    Martinez-Gines, Maria Luisa
    Arroyo, Rafael
    Otano-Martinez, Maria Angeles
    Brieva-Ruiz, Luis
    Gomez-Gutierrez, Montserrat
    Rodriguez-Antiguedad, Alfredo
    Sanchez-Seco, Victoria Galan
    Costa-Frossard, Lucienne
    Hernandez-Perez, Miguel Angel
    Landete-Pascual, Lamberto
    Gonzalez-Platas, Montserrat
    Meca-Lallana, Jose E.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
  • [22] Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?
    Cohen, Jeffrey A.
    Cross, Anne H.
    JAMA NEUROLOGY, 2023, 80 (07) : 669 - 672
  • [23] Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
    Massimo Filippi
    Maria Pia Amato
    Diego Centonze
    Paolo Gallo
    Claudio Gasperini
    Matilde Inglese
    Francesco Patti
    Carlo Pozzilli
    Paolo Preziosa
    Maria Trojano
    Journal of Neurology, 2022, 269 : 6690 - 6691
  • [24] Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
    Massimo Filippi
    Romano Danesi
    Tobias Derfuss
    Martin Duddy
    Paolo Gallo
    Ralf Gold
    Eva Kubala Havrdová
    Barbara Kornek
    Francesco Saccà
    Mar Tintoré
    Jörg Weber
    Maria Trojano
    Journal of Neurology, 2022, 269 : 1670 - 1677
  • [25] Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Petereit, Hela-Felicitas
    Tumani, Hayrettin
    Zettl, Uwe K.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [26] Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study
    Li, Jieni
    Hutton, George J.
    Varisco, Tyler J.
    Lin, Ying
    Essien, Ekere J.
    Aparasu, Rajender R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025, 117 (02) : 561 - 569
  • [27] Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Piquet, Amanda L.
    Corboy, John R.
    Vollmer, Timothy L.
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [28] Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
    Kvistad, Silje Agnethe Stokke
    Burman, Joachim
    Lehmann, Anne Kristine
    Tolf, Andreas
    Zjukovskaja, Christina
    Melve, Guro Kristin
    Bo, Lars
    Torkildsen, Oivind
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (08): : 844 - 848
  • [29] Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
    Konig, M.
    Lorentzen, A.
    Tran, T.
    Schikora-Rustad, S.
    Leiknes, I. J.
    Vaage, E. B.
    Mygland, A.
    Aaberge, I. S.
    Berge, T.
    Skattebol, L.
    Harbo, H. F.
    Andersen, J. T.
    Vaage, J. T.
    Celius, E. G.
    Munthe, L. A.
    Lund-Johansen, F.
    Nygaard, G. O.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 561 - 561
  • [30] IMPACT OF EARLY DISEASE MODIFYING THERAPY (DMT) TREATMENT INITIATION AND USE OF HIGH-EFFICACY (HET) ON CLINICAL AND HEALTH OUTCOMES IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
    Chang, A.
    Maiese, B. A.
    Mody, L.
    Cheadle, A.
    Brown, B.
    Deshpande, C.
    VALUE IN HEALTH, 2020, 23 : S623 - S623
12345